GlassScriptPhysician profile
Allen R Gardner
NPI 1326072000
$737.08
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $233 · 2021: $111.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $166.63 | 2019-2020 | |
| Amgen INC. | $106.39 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $67.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $67.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.41 | 2020 | |
| Radius Health, INC. | $39.81 | 2020-2021 | |
| Novo Nordisk INC | $37.16 | 2019 | |
| Medicure Pharma INC. | $32.84 | 2021 | |
| Amarin Pharma, INC. | $25.60 | 2020-2021 | |
| Esperion Therapeutics, INC. | $17.07 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.99 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.43 | 2021 | |
| Ge Healthcare | $14.65 | 2020 | |
| Janssen Biotech, INC. | $14.55 | 2019 | |
| Daiichi Sankyo INC. | $14.32 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.46 | 2019 | |
| Boston Scientific Corporation | $11.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2019 | |
| Allergan, INC. | $11.41 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.